Literature DB >> 26587314

Triggering co-stimulation directly in melanoma tumor fragments drives CD8+ tumor-infiltrating lymphocyte expansion with improved effector-memory properties.

Jessica Ann Chacon1, Amod A Sarnaik2, Shari Pilon-Thomas2, Laszlo Radvanyi3.   

Abstract

TIL from solid tumors can express activation/co-stimulatory molecules like 4-1BB/CD137, a sign of recent antigenic stimulation in the tumor microenvironment (TME). This activated state can be exploited ex vivo to enhance the expansion of tumor-reactive CD8+ TIL for adoptive cell therapy through direct addition of immunomodulators to tumor fragments in culture.

Entities:  

Keywords:  4–1BB; Tumor-Infiltrating Lymphocytes; adoptive T-cell therapy; co-stimulation

Year:  2015        PMID： 26587314      PMCID： PMC4635692          DOI： 10.1080/2162402X.2015.1040219

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation.

Authors:  Sung-Joo Park; Takayuki Nakagawa; Hidemitsu Kitamura; Toru Atsumi; Hokuto Kamon; Shin-Ichiro Sawa; Daisuke Kamimura; Naoko Ueda; Yoichiro Iwakura; Katsuhiko Ishihara; Masaaki Murakami; Toshio Hirano
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

2.  Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.

Authors:  Peter A Prieto; Katherine H Durflinger; John R Wunderlich; Steven A Rosenberg; Mark E Dudley
Journal:  J Immunother       Date:  2010-06       Impact factor: 4.456

3.  Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.

Authors:  Jessica Ann Chacon; Amod A Sarnaik; Jie Qing Chen; Caitlin Creasy; Charuta Kale; John Robinson; Jeffrey Weber; Patrick Hwu; Shari Pilon-Thomas; Laszlo Radvanyi
Journal:  Clin Cancer Res       Date:  2014-12-03       Impact factor: 12.531

4.  CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

Authors:  Qunrui Ye; De-Gang Song; Mathilde Poussin; Tori Yamamoto; Andrew Best; Chunsheng Li; George Coukos; Daniel J Powell
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

5.  Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.

Authors:  Mark E Dudley; John R Wunderlich; Thomas E Shelton; Jos Even; Steven A Rosenberg
Journal:  J Immunother       Date:  2003 Jul-Aug       Impact factor: 4.456

Review 6.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

Review 7.  Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.

Authors:  Chao Wang; Gloria H Y Lin; Ann J McPherson; Tania H Watts
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

8.  Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.

Authors:  Michael A Curran; Myoungjoo Kim; Welby Montalvo; Aymen Al-Shamkhani; James P Allison
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

9.  Interferon gamma is required for activation-induced death of T lymphocytes.

Authors:  Yosef Refaeli; Luk Van Parijs; Stephen I Alexander; Abul K Abbas
Journal:  J Exp Med       Date:  2002-10-07       Impact factor: 14.307

10.  Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves.

Authors:  Alexandra Sevko; Viktor Umansky
Journal:  J Cancer       Date:  2012-11-30       Impact factor: 4.207
  10 in total
  4 in total

Review 1.  Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process.

Authors:  Emily L Hopewell; Cheryl Cox; Shari Pilon-Thomas; Linda L Kelley
Journal:  Cytotherapy       Date:  2018-12-01       Impact factor: 5.414

2.  Detection of Productively Rearranged TcR-α V-J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells.

Authors:  Thomas R Gill; Mohammad D Samy; Shanitra N Butler; James A Mauro; Wade J Sexton; George Blanck
Journal:  Cancer Inform       Date:  2016-02-25

3.  Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma.

Authors:  Rolando Pérez-Lorenzo; Stephanie O Erjavec; Angela M Christiano; Raphael Clynes
Journal:  Oncotarget       Date:  2021-01-19

4.  S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity.

Authors:  Jinhua Zhang; Kun Song; Jun Wang; Yanan Li; Shuangqing Liu; Chengliang Dai; Lieping Chen; Shengdian Wang; Zhihai Qin
Journal:  Oncoimmunology       Date:  2018-01-23       Impact factor: 8.110
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.